Details

Autor(en) / Beteiligte

• Langbein, Thomas
• Chaussé, Guillaume
• Baum, Richard P

Titel

Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies

Ist Teil von

• Journal of Nuclear Medicine, 2018-08, Vol.59 (8), p.1172-1173

Ort / Verlag

United States: Society of Nuclear Medicine

Erscheinungsjahr

2018

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Since the first clinical use of 131I-labeled prostate-specific membrane antigen (PSMA), xerostomia has been identified as a relevant side effect of PSMA radioligand therapies (PRLTs) for metastatic castration-resistant prostate cancer. Given the remarkable progress when using 177Lu-labeled compounds and the impressive results of 225Ac-PSMA PRLT, Langbein et al believe that effective preventive strategies for salivary gland (SG) toxicity need to be developed to preserve the extremely attractive side effect profile of PRLT as compared with standard treatments. Although the highest off-target uptake is seen in the SG, multicenter data on 177Lu-PSMA PRLT revealed only mild to moderate reversible xerostomia in 8% of patients. In a systematic analysis, the group confirmed these findings.